- Collegium Announces $35 Million Accelerated Share Repurchase Program
- Collegium Reports First Quarter 2024 Financial Results
- Collegium Announces CEO Transition
- Collegium Announces Authorized Generic Agreement with Hikma Pharmaceuticals USA Inc. for Nucynta® and Nucynta® ER
- Collegium to Report First Quarter 2024 Financial Results on May 9, 2024
- Collegium Pharmaceutical, Inc. Announces Redemption of Outstanding 2.625% Convertible Senior Notes Due 2026
- Collegium to Participate in 23rd Annual Needham Virtual Healthcare Conference
- Collegium Reports Record Fourth Quarter and Full-Year 2023 Financial Results
- Collegium to Report Fourth Quarter and Full-Year 2023 Financial Results on February 22, 2024
- Collegium Provides 2024 Financial Guidance
More ▼
Key statistics
As of last trade Collegium Pharmaceutical Inc (COLL:NSQ) traded at 33.91, -17.19% below its 52-week high of 40.95, set on Mar 28, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 34.45 |
---|---|
High | 34.55 |
Low | 33.41 |
Bid | 33.90 |
Offer | 33.95 |
Previous close | 34.18 |
Average volume | 758.43k |
---|---|
Shares outstanding | 32.72m |
Free float | 32.19m |
P/E (TTM) | 16.60 |
Market cap | 1.12bn USD |
EPS (TTM) | 2.06 USD |
Data delayed at least 15 minutes, as of May 23 2024 18:34 BST.
More ▼